vs
KRONOS WORLDWIDE INC（KRO）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是KRONOS WORLDWIDE INC的1.5倍（$622.0M vs $418.3M），Royalty Pharma plc净利率更高（34.4% vs -19.8%，领先54.2%），Royalty Pharma plc同比增速更快（4.8% vs -1.1%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -6.5%）
克罗诺斯全球（原克罗诺斯公司）是一家美国跨国企业，总部位于美国马萨诸塞州洛厄尔，专注于提供劳动力管理与人力资本管理云服务，在全球拥有超过6000名员工，是该领域知名的服务提供商。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
KRO vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.5倍
$418.3M
营收增速更快
RPRX
高出5.9%
-1.1%
净利率更高
RPRX
高出54.2%
-19.8%
两年增速更快
RPRX
近两年复合增速
-6.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $418.3M | $622.0M |
| 净利润 | $-82.8M | $214.2M |
| 毛利率 | -0.9% | — |
| 营业利润率 | -15.1% | 62.4% |
| 净利率 | -19.8% | 34.4% |
| 营收同比 | -1.1% | 4.8% |
| 净利润同比 | -527.3% | 2.9% |
| 每股收益（稀释后） | $-0.72 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KRORPRX
| Q4 25 | $418.3M | $622.0M | ||
| Q3 25 | $456.9M | $609.3M | ||
| Q2 25 | $494.4M | $578.7M | ||
| Q1 25 | $489.8M | $568.2M | ||
| Q4 24 | $423.1M | $593.6M | ||
| Q3 24 | $484.7M | $564.7M | ||
| Q2 24 | $500.5M | $537.3M | ||
| Q1 24 | $478.8M | $568.0M |
净利润KRORPRX
| Q4 25 | $-82.8M | $214.2M | ||
| Q3 25 | $-37.0M | $288.2M | ||
| Q2 25 | $-9.2M | $30.2M | ||
| Q1 25 | $18.1M | $238.3M | ||
| Q4 24 | $-13.2M | $208.2M | ||
| Q3 24 | $71.8M | $544.0M | ||
| Q2 24 | $19.5M | $102.0M | ||
| Q1 24 | $8.1M | $4.8M |
毛利率KRORPRX
| Q4 25 | -0.9% | — | ||
| Q3 25 | 10.3% | — | ||
| Q2 25 | 12.7% | — | ||
| Q1 25 | 21.8% | — | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 20.9% | — | ||
| Q2 24 | 20.0% | — | ||
| Q1 24 | 14.9% | — |
营业利润率KRORPRX
| Q4 25 | -15.1% | 62.4% | ||
| Q3 25 | -4.2% | 70.1% | ||
| Q2 25 | 1.5% | 36.3% | ||
| Q1 25 | 7.8% | 94.0% | ||
| Q4 24 | 6.8% | 60.9% | ||
| Q3 24 | 8.0% | — | ||
| Q2 24 | 7.2% | 50.2% | ||
| Q1 24 | 4.1% | -13.0% |
净利率KRORPRX
| Q4 25 | -19.8% | 34.4% | ||
| Q3 25 | -8.1% | 47.3% | ||
| Q2 25 | -1.9% | 5.2% | ||
| Q1 25 | 3.7% | 41.9% | ||
| Q4 24 | -3.1% | 35.1% | ||
| Q3 24 | 14.8% | 96.3% | ||
| Q2 24 | 3.9% | 19.0% | ||
| Q1 24 | 1.7% | 0.8% |
每股收益（稀释后）KRORPRX
| Q4 25 | $-0.72 | $0.49 | ||
| Q3 25 | $-0.32 | $0.67 | ||
| Q2 25 | $-0.08 | $0.07 | ||
| Q1 25 | $0.16 | $0.55 | ||
| Q4 24 | $-0.11 | $0.46 | ||
| Q3 24 | $0.62 | $1.21 | ||
| Q2 24 | $0.17 | $0.23 | ||
| Q1 24 | $0.07 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $33.2M | $618.7M |
| 总债务越低越好 | $557.4M | $9.0B |
| 股东权益账面价值 | $751.1M | $9.7B |
| 总资产 | $1.8B | $19.6B |
| 负债/权益比越低杠杆越低 | 0.74× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资KRORPRX
| Q4 25 | $33.2M | $618.7M | ||
| Q3 25 | $27.7M | $938.9M | ||
| Q2 25 | $18.9M | $631.9M | ||
| Q1 25 | $20.5M | $1.1B | ||
| Q4 24 | $106.7M | $929.0M | ||
| Q3 24 | $94.8M | $950.1M | ||
| Q2 24 | $133.8M | $1.8B | ||
| Q1 24 | $120.7M | $843.0M |
总债务KRORPRX
| Q4 25 | $557.4M | $9.0B | ||
| Q3 25 | $626.2M | $8.9B | ||
| Q2 25 | $589.3M | $8.0B | ||
| Q1 25 | $557.2M | $7.6B | ||
| Q4 24 | $507.4M | $7.6B | ||
| Q3 24 | $554.3M | $7.6B | ||
| Q2 24 | $423.7M | $7.6B | ||
| Q1 24 | $426.9M | $6.1B |
股东权益KRORPRX
| Q4 25 | $751.1M | $9.7B | ||
| Q3 25 | $804.7M | $9.6B | ||
| Q2 25 | $846.8M | $9.5B | ||
| Q1 25 | $847.0M | $9.8B | ||
| Q4 24 | $817.0M | $10.3B | ||
| Q3 24 | $847.4M | $10.3B | ||
| Q2 24 | $774.6M | $9.8B | ||
| Q1 24 | $774.4M | $9.9B |
总资产KRORPRX
| Q4 25 | $1.8B | $19.6B | ||
| Q3 25 | $1.9B | $19.3B | ||
| Q2 25 | $1.9B | $18.3B | ||
| Q1 25 | $1.9B | $17.6B | ||
| Q4 24 | $1.9B | $18.2B | ||
| Q3 24 | $1.9B | $18.0B | ||
| Q2 24 | $1.7B | $17.7B | ||
| Q1 24 | $1.7B | $16.1B |
负债/权益比KRORPRX
| Q4 25 | 0.74× | 0.92× | ||
| Q3 25 | 0.78× | 0.93× | ||
| Q2 25 | 0.70× | 0.84× | ||
| Q1 25 | 0.66× | 0.78× | ||
| Q4 24 | 0.62× | 0.74× | ||
| Q3 24 | 0.65× | 0.74× | ||
| Q2 24 | 0.55× | 0.78× | ||
| Q1 24 | 0.55× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $92.1M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $81.9M | — |
| 自由现金流率自由现金流/营收 | 19.6% | — |
| 资本支出强度资本支出/营收 | 2.4% | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | $-40.4M | — |
8季度趋势，按日历期对齐
经营现金流KRORPRX
| Q4 25 | $92.1M | $827.1M | ||
| Q3 25 | $-7.9M | $702.6M | ||
| Q2 25 | $20.7M | $364.0M | ||
| Q1 25 | $-102.4M | $596.1M | ||
| Q4 24 | $49.3M | $742.5M | ||
| Q3 24 | $28.3M | $703.6M | ||
| Q2 24 | $38.2M | $658.2M | ||
| Q1 24 | $-43.3M | $664.6M |
自由现金流KRORPRX
| Q4 25 | $81.9M | — | ||
| Q3 25 | $-17.4M | — | ||
| Q2 25 | $9.5M | — | ||
| Q1 25 | $-114.4M | — | ||
| Q4 24 | $37.0M | — | ||
| Q3 24 | $19.2M | — | ||
| Q2 24 | $34.8M | — | ||
| Q1 24 | $-48.0M | — |
自由现金流率KRORPRX
| Q4 25 | 19.6% | — | ||
| Q3 25 | -3.8% | — | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | -23.4% | — | ||
| Q4 24 | 8.7% | — | ||
| Q3 24 | 4.0% | — | ||
| Q2 24 | 7.0% | — | ||
| Q1 24 | -10.0% | — |
资本支出强度KRORPRX
| Q4 25 | 2.4% | — | ||
| Q3 25 | 2.1% | — | ||
| Q2 25 | 2.3% | — | ||
| Q1 25 | 2.4% | — | ||
| Q4 24 | 2.9% | — | ||
| Q3 24 | 1.9% | — | ||
| Q2 24 | 0.7% | — | ||
| Q1 24 | 1.0% | — |
现金转化率KRORPRX
| Q4 25 | — | 3.86× | ||
| Q3 25 | — | 2.44× | ||
| Q2 25 | — | 12.06× | ||
| Q1 25 | -5.66× | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | 0.39× | 1.29× | ||
| Q2 24 | 1.96× | 6.45× | ||
| Q1 24 | -5.35× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KRO
暂无分部数据
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
